NanoBioMagnetics (NBMI) is a privately held nanobiotechnology R&D company focusing on the use of nanotools in the development of advanced healthcare applications, referred to as organ-assisting-device (OAD) technologies. The company's business model calls for the development and validation of OAD applications that, when fully developed, can be spun off with pharma partners as independent business units. An equity investment in NBMI will likewise provide the investor with an equity share in such business spin-offs. And, as the business status and financial climate permit, the spin-off will proceed with a public or private offering to support business growth and expansion.
NBMI periodically issues Private Placement Memorandums (PPM) to raise capital to support R&D activities and business operations. NBMI will remain the repository for all Intellectual property with business unit spin-offs receiving exclusive rights to produce and market their respective OAD product technologies.
NBMI is currently seeking $5MM in equity investments over the next five years to advance its OAD applications to the IND and commercialization stage.
Interested individuals and qualified investors may contact the Company for details of current stock offerings.
